AOD-9604 side effects and safety context

No serious, distinctive side-effect profile has been documented for AOD-9604 — but that statement needs its context: the human studies were short, designed to test an obesity drug that ultimately failed, and their detailed safety data were never published in a peer-reviewed journal. What can be said is that its early-2000s clinical program (phase IIa trials were underway by 2002; Current Opinion in Investigational Drugs 2004) did not surface safety findings dramatic enough to become part of the public record, and that the reported effects in community use are the generic ones of any subcutaneous peptide: injection-site redness, swelling, and occasional headache or nausea.

It helps to sort the evidence by quality rather than list symptoms:

• Animal studies (peer-reviewed): in obese Zucker rats, 19 days of oral AOD-9604 increased fat breakdown without impairing insulin sensitivity on euglycemic-clamp testing — the glucose problem seen with full growth hormone did not appear (Hormone Research 2000).
• Human trials (unpublished): the developer's obesity program included several hundred participants, but no peer-reviewed human safety or efficacy paper exists on PubMed. "Described as well tolerated" claims trace back to company communications, not journals.
• Reviews: a 2026 Sports Medicine review of unapproved peptides puts it plainly — favorable animal signals, but "rigorous human safety data are scarce, and there is potential for serious harm to patients" (Sports Medicine 2026).

Because AOD-9604 is only the C-terminal fragment of growth hormone, it was engineered to skip GH's problem effects: it is not reported to raise IGF-1, does not promote tissue growth, and did not disturb glucose handling in the animal work. Those absences are the main reason its safety conversation is quieter than for GH itself or for GH secretagogues. But an absence of designed-in effects is not a demonstration of long-term safety — chronic human exposure has simply never been characterized.

For athletes, the clearest documented risk is regulatory, not medical. AOD-9604 is banned by the World Anti-Doping Agency (it falls under S0, the category for substances with no current approval for human therapeutic use), and anti-doping laboratories have built urine detection methods for it after vials were confiscated in the United States (Drug Testing and Analysis 2015). The compound became widely known through the 2013 Essendon supplements scandal in Australian football. A tested athlete using AOD-9604 risks a violation regardless of whether the peptide does anything.

Everything above concerns the molecule. Vials sold online add a second layer of uncertainty that has nothing to do with AOD-9604's pharmacology: identity, purity, dose accuracy, and sterility of research-grade material are unverified, and the confiscated-vial finding above shows such products circulate outside any oversight. Combined with the absence of published human data, this is why the safety question for AOD-9604 cannot honestly be answered "it's safe" — only "no one has properly measured it." Related reading: AOD-9604 dosing education and the research overview.